消息面上，歌礼制药发布公告称，控股股东持有的JJW12 Limited将以先旧后新方式向不少于六名承配 人，先出售5240万股股份，占公司现有已发行股本约5.44%；同时，又将认购公司2882万股新股，占经 扩大后股本约2.9%，每股作价16.45港元，较公司8月18日收市价折让9.9%，集资净额约4.68亿港元，其 中约90%用于皮下注射多肽及口服多肽候选药物有关之肥胖症临床试验研发，其余约10%作营运资金及 一般公司用途。完成后，JJW12 Limited持股将由约53.38%降至49.45%，控股股东总持股由62.21%降至 58.03%。 智通财经APP获悉，歌礼制药-B(01672)低开逾9%，截至发稿，跌9.64%，报16.5港元，成交额8.68亿港 元。 ...

Group 1 - Company Gilead Sciences-B (01672) announced a placement and subscription agreement on August 19, 2025, involving the sale of 52.4 million shares at a price of HKD 16.45 per share [1][2] - The total number of shares being placed represents approximately 5.44% of the company's issued share capital as of the announcement date, excluding treasury shares [2] - The subscription involves the issuance of 28.82 million new shares, which accounts for about 2.90% of the enlarged share capital post-placement and subscription [2] Group 2 - The placement price of HKD 16.45 per share reflects a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [2] - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital, excluding treasury shares [2] - The net proceeds from the subscription are expected to be around HKD 468 million, with about 90% allocated for clinical trial development related to obesity treatments and 10% for general corporate purposes [2]

Core Viewpoint - The company, Gilead Sciences-B (01672), has entered into a placement and subscription agreement to sell and issue shares, which will result in a significant change in shareholding structure and raise funds for clinical trials and operational needs [1][2]. Group 1: Share Placement and Subscription Details - The total number of shares to be placed is 52.4 million, representing approximately 5.44% of the company's issued share capital as of the announcement date [2]. - The subscription involves 28.82 million new shares, accounting for about 2.90% of the enlarged issued share capital post-placement and subscription [2]. - The placement price is set at HKD 16.45 per share, which is a discount of approximately 9.9% compared to the closing price of HKD 18.26 on the last trading day [2]. Group 2: Shareholding Changes - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital [2]. - The total shareholding percentage of the controlling shareholder will reduce from about 62.21% to approximately 58.03% after the issuance of the new shares [2]. Group 3: Use of Proceeds - The net proceeds from the subscription are expected to be around HKD 468 million after deducting commissions and estimated expenses [2]. - Approximately 90% of the net proceeds is intended for the development of clinical trials related to subcutaneous and oral peptide candidates for obesity [2]. - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [2].

Core Viewpoint - The company, Gilead Sciences, announced a placement and subscription agreement for the sale of 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

Core Viewpoint - The company, Gilead Sciences (stock code: 1672), announced a financing plan through the placement of existing shares and the issuance of new shares, raising approximately HKD 470 million for clinical trials and operational needs [1] Group 1: Financing Details - The company plans to place 52,400,000 existing shares and issue 28,820,000 new shares at a price of HKD 16.45 per share, representing a discount of about 9.9% compared to the closing price of HKD 18.26 on August 18, 2025 [1] - The placement of existing shares accounts for approximately 5.44% of the current issued share capital, while the new shares will represent about 2.99% of the existing share capital [1] - The funds raised will be allocated with approximately HKD 420 million for clinical trials related to subcutaneous and oral peptide candidates for obesity, and about HKD 50 million for working capital and other general corporate purposes [1] Group 2: Regulatory and Completion Aspects - The issuance is conducted under a general mandate granted by the shareholders' meeting, and the subscription will be completed upon meeting relevant conditions, but no later than 14 days after August 19, 2025 [1]

Group 1 - Company Gilead Sciences-B (01672.HK) announced a placement and subscription agreement involving the sale of 52.4 million shares at a price of HKD 16.45 per share, which represents a discount of approximately 9.9% compared to the closing price of HKD 18.26 on August 18 [1] - The total number of shares being placed represents about 5.44% of the company's issued share capital, while the subscription of 28.82 million shares accounts for approximately 2.90% of the enlarged issued share capital [1] - Following the completion of the placement and subscription, the controlling shareholder's stake will decrease from approximately 62.21% to about 58.03% of the issued share capital [2] Group 2 - The total expected proceeds from the subscription amount to approximately HKD 474 million, with a net amount of about HKD 468 million after deducting commissions and estimated expenses [2] - Approximately 90% of the net proceeds from the subscription are intended for clinical trial development related to subcutaneous and oral peptide candidates for obesity, while about 10% is suggested for working capital and other general corporate purposes [2]

Core Viewpoint - The company, Geely Pharmaceutical, announced a placement and subscription agreement to sell 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18, 2023 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約，亦並非擬用作邀請提出 相關要約或邀請。本公告或其任何副本概不得直接或間接帶入美國或於美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）派發。尤其是，本公告並不構成亦並非在美國或其他地方出 售證券的要約或招攬購買或認購證券的任何要約。除非已根據一九三三年美國證券法（經修訂） 登記或獲豁免登記，否則證券不得在美國提呈發售或出售。於美國進行的任何證券公開發售將 僅以招股章程的方式進行，該招股章程可向證券發行人或賣方取得，並載有發行人及管理層的 詳細資料以及財務資料。本公司無意於美國公開發售本公告所述證券。 Ascletis Pharma Inc. 歌禮製藥有限公司 （ 於開曼群島註冊成立的有限公司 ） （股份代號：1672） (1)根據一般授權配售現有股份及補足認購新股份 及 (2)補足賣方股份出售 獨家整體協調人及獨家配售代理 由於配售及認購的完 ...

Core Viewpoint - The stock price of Gilead Sciences-B (01672) has increased over 3%, with a cumulative rise of over 100% in the past month, reflecting strong market performance and positive developments in its drug pipeline [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, showing a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a reduction of 32.5% compared to the previous year [1] - The loss per share was reported at 9.14 cents [1] Drug Development Progress - Significant advancements were made in the metabolic disease pipeline, immune disease pipeline, and expanded indication product pipeline [1] - The ASC30 oral tablet for obesity treatment demonstrated a weight reduction of up to 6.5% after 28 days in a U.S. Phase Ib study, indicating its potential as a best-in-class candidate for obesity treatment [1] - The company initiated a U.S. Phase IIa study and rapidly enrolled 125 participants within just over a month [1] - The ASC30 subcutaneous injection, administered once monthly or less frequently, showed a half-life of 36 days in obesity patients during a U.S. Phase Ib study, supporting its potential for less frequent dosing [1]

Core Viewpoint - The stock price of Gilead Sciences-B (01672) has increased over 3%, with a cumulative rise of over 100% in the past month, reflecting strong market performance and investor interest [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, showing a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a reduction of 32.5% compared to the previous year [1] - The loss per share was reported at 9.14 cents [1] Product Development Progress - Significant advancements were made in the metabolic disease pipeline, immune disease pipeline, and expansion indication product pipeline [1] - The ASC30 oral tablet for obesity treatment demonstrated a weight reduction of up to 6.5% after 28 days in a U.S. Phase Ib study, indicating its potential as a best-in-class candidate for obesity treatment [1] - The company has initiated a U.S. Phase IIa study and rapidly enrolled 125 participants within just over a month [1] - The ASC30 subcutaneous injection for obesity treatment showed a half-life of 36 days after a single injection in patients, supporting the feasibility of monthly or less frequent dosing [1]